Protalix Biotherapeutics Inc (PLX) — Capital Reinvestment Ratio

Latest as of December 2025: 0.61x

Protalix Biotherapeutics Inc (PLX) has a Capital Reinvestment Ratio of 0.61x as of December 2025, meaning it reinvests 1% of its operating cash flow ($2.03 Million) in capital expenditures ($1.24 Million). See how much free cash does Protalix Biotherapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.61x
Capex / Operating Cash Flow

Operating Cash Flow

$2.03 Million
USD

Capital Expenditures

$1.24 Million
USD

Data as of

Dec 2025
Most recent filing

Protalix Biotherapeutics Inc Capital Reinvestment Ratio (2009–2024)

This chart tracks Protalix Biotherapeutics Inc's Capital Reinvestment Ratio across 3 annual periods.

Annual Capital Reinvestment Ratio for Protalix Biotherapeutics Inc (2009–2024)

Year-by-year Capital Reinvestment Ratio for Protalix Biotherapeutics Inc from 2009 to 2024. For live market cap and broader valuation context, see Protalix Biotherapeutics Inc stock valuation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2024 0.15x $8.67 Million $1.28 Million ▼ -95.5%
2012 3.26x $635.00K $2.07 Million ▲ +2236.8%
2009 0.14x $44.45 Million $6.20 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow